JP6457523B2 - 医薬組成物のためのスルホキシイミン置換キナゾリン - Google Patents
医薬組成物のためのスルホキシイミン置換キナゾリン Download PDFInfo
- Publication number
- JP6457523B2 JP6457523B2 JP2016536528A JP2016536528A JP6457523B2 JP 6457523 B2 JP6457523 B2 JP 6457523B2 JP 2016536528 A JP2016536528 A JP 2016536528A JP 2016536528 A JP2016536528 A JP 2016536528A JP 6457523 B2 JP6457523 B2 JP 6457523B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- optionally substituted
- phenyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 **C1C(*)COC1 Chemical compound **C1C(*)COC1 0.000 description 25
- NNIIKJUKQFIODU-DAABDDCCSA-N CC(C)(C)OC(N(C1)C2C(C)(C)[Si+](C)(C)O[C@@H]2[C@H]1Oc1c([C@H](C=[O]=C)[O-])ccc(F)c1)=O Chemical compound CC(C)(C)OC(N(C1)C2C(C)(C)[Si+](C)(C)O[C@@H]2[C@H]1Oc1c([C@H](C=[O]=C)[O-])ccc(F)c1)=O NNIIKJUKQFIODU-DAABDDCCSA-N 0.000 description 1
- OBNHXOMSMPEDBC-NXEZZACHSA-N CC(N(C[C@H]1O)C[C@H]1Oc1ncccc1[N+](O)=O)=O Chemical compound CC(N(C[C@H]1O)C[C@H]1Oc1ncccc1[N+](O)=O)=O OBNHXOMSMPEDBC-NXEZZACHSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N CN(C)C(OC)OC Chemical compound CN(C)C(OC)OC ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- CYMSXYAVRAZSCG-SKDRFNHKSA-N CO[C@H](C=C1)OC[C@@H]1Oc1cc(F)ccc1[N+]([O-])=O Chemical compound CO[C@H](C=C1)OC[C@@H]1Oc1cc(F)ccc1[N+]([O-])=O CYMSXYAVRAZSCG-SKDRFNHKSA-N 0.000 description 1
- WFVQOYLPHHYMBC-CRCLSJGQSA-N CO[C@H](COC1)[C@H]1I Chemical compound CO[C@H](COC1)[C@H]1I WFVQOYLPHHYMBC-CRCLSJGQSA-N 0.000 description 1
- PXBRXYBYWGINOF-ACZMJKKPSA-N C[C@@H](C1)[C@H]2OC[C@@H]1C2 Chemical compound C[C@@H](C1)[C@H]2OC[C@@H]1C2 PXBRXYBYWGINOF-ACZMJKKPSA-N 0.000 description 1
- IELRVSHSMOMLQC-PHDIDXHHSA-N C[C@H](COC1)[C@@H]1OC Chemical compound C[C@H](COC1)[C@@H]1OC IELRVSHSMOMLQC-PHDIDXHHSA-N 0.000 description 1
- RLVODLKUPPGLFA-HCCKASOXSA-N Cc(c(/[O]=C\C(COC1)[C@@H]1O)c1)ccc1F Chemical compound Cc(c(/[O]=C\C(COC1)[C@@H]1O)c1)ccc1F RLVODLKUPPGLFA-HCCKASOXSA-N 0.000 description 1
- WCORTMMJOYEIPA-YGPZHTELSA-N Cc(c(OCC(COC1)[C@@H]1O)n1)ccc1Cl Chemical compound Cc(c(OCC(COC1)[C@@H]1O)n1)ccc1Cl WCORTMMJOYEIPA-YGPZHTELSA-N 0.000 description 1
- KECKCXSEHJTSJN-ONGXEEELSA-N Cc(c(O[C@@H](COC1)[C@H]1O)c1)ccc1Cl Chemical compound Cc(c(O[C@@H](COC1)[C@H]1O)c1)ccc1Cl KECKCXSEHJTSJN-ONGXEEELSA-N 0.000 description 1
- IUUDFUXYAURAJP-ONGXEEELSA-N Cc(c(O[C@@H](COC1)[C@H]1O)c1)ccc1F Chemical compound Cc(c(O[C@@H](COC1)[C@H]1O)c1)ccc1F IUUDFUXYAURAJP-ONGXEEELSA-N 0.000 description 1
- HQWCJAHNSGGZJV-UHFFFAOYSA-N Cc1cc2ccc1[o]2 Chemical compound Cc1cc2ccc1[o]2 HQWCJAHNSGGZJV-UHFFFAOYSA-N 0.000 description 1
- IWBWTFZBDFRGSH-VEDVMXKPSA-N Cc1cccnc1OC(COC1)[C@@H]1O Chemical compound Cc1cccnc1OC(COC1)[C@@H]1O IWBWTFZBDFRGSH-VEDVMXKPSA-N 0.000 description 1
- IWBWTFZBDFRGSH-IUCAKERBSA-N Cc1cccnc1O[C@@H](COC1)[C@H]1O Chemical compound Cc1cccnc1O[C@@H](COC1)[C@H]1O IWBWTFZBDFRGSH-IUCAKERBSA-N 0.000 description 1
- HQVKXDYSIGDGSY-IMJSIDKUSA-N N[C@@H](COC1)[C@H]1O Chemical compound N[C@@H](COC1)[C@H]1O HQVKXDYSIGDGSY-IMJSIDKUSA-N 0.000 description 1
- AYRNMFATNSCONU-RGENBBCFSA-O Nc(ccc(F)c1)c1[OH+]C(COC1)[C@H]1C#N Chemical compound Nc(ccc(F)c1)c1[OH+]C(COC1)[C@H]1C#N AYRNMFATNSCONU-RGENBBCFSA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13195720.1 | 2013-12-04 | ||
| EP13195720 | 2013-12-04 | ||
| PCT/EP2014/075890 WO2015082324A1 (en) | 2013-12-04 | 2014-11-28 | Sulfoximine substituted quinazolines for pharmaceutical compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539148A JP2016539148A (ja) | 2016-12-15 |
| JP2016539148A5 JP2016539148A5 (enExample) | 2017-11-30 |
| JP6457523B2 true JP6457523B2 (ja) | 2019-01-23 |
Family
ID=49726564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536528A Expired - Fee Related JP6457523B2 (ja) | 2013-12-04 | 2014-11-28 | 医薬組成物のためのスルホキシイミン置換キナゾリン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10093660B2 (enExample) |
| EP (1) | EP3077383B1 (enExample) |
| JP (1) | JP6457523B2 (enExample) |
| AU (1) | AU2014359456B2 (enExample) |
| CA (1) | CA2929742C (enExample) |
| ES (1) | ES2693520T3 (enExample) |
| WO (1) | WO2015082324A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6479854B2 (ja) * | 2014-05-07 | 2019-03-06 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 医薬組成物のためのスルホキシイミン置換キナゾリン |
| AR117788A1 (es) * | 2019-01-14 | 2021-08-25 | Pi Industries Ltd | Compuestos de fenilamidina 3-sustituida, preparación y uso |
| CN112812136B (zh) * | 2019-11-15 | 2022-04-12 | 武汉光谷亚太医药研究院有限公司 | 新型2,3-二氢化茚衍生化合物、制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3987192A (en) | 1974-01-07 | 1976-10-19 | The Upjohn Company | Compositions and process of treatment |
| US5602118A (en) | 1993-03-16 | 1997-02-11 | American Cyanamid Company | 2-thiosubstituted carbapenems |
| CA2188772A1 (en) | 1994-06-08 | 1995-12-14 | Balreddy Kamireddy | Cyclic sulfonamide herbicides |
| SE0102147D0 (sv) | 2001-06-18 | 2001-06-18 | Pharmacia Ab | New methods |
| AU2002363175A1 (en) | 2001-10-29 | 2003-05-12 | Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung | Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism |
| MXPA04008403A (es) | 2002-03-01 | 2004-11-26 | Pfizer | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso. |
| GB0315587D0 (en) | 2003-07-03 | 2003-08-13 | Univ Dundee | Anti-inflammatory assay and compounds |
| CN101648906B (zh) | 2004-04-08 | 2012-07-11 | 美国陶氏益农公司 | 杀虫用n-取代亚磺酰亚胺 |
| EP1746099A1 (en) | 2004-12-23 | 2007-01-24 | DeveloGen Aktiengesellschaft | Mnk1 or Mnk2 inhibitors |
| AU2006261082B2 (en) * | 2005-06-22 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Thienopyrimidines for pharmaceutical compositions |
| EP1991547A2 (en) | 2006-03-09 | 2008-11-19 | Pharmacopeia, Inc. | 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders |
| CA2651898A1 (en) | 2006-04-07 | 2007-10-18 | Develogen Aktiengesellschaft | Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
| DE602007004618D1 (de) | 2006-06-22 | 2010-03-18 | Biovitrum Ab Publ | Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren |
| DE102007024470A1 (de) | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren |
| US8003787B2 (en) * | 2007-05-24 | 2011-08-23 | Bayer Schering Pharma Ag | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors |
| JP2011510033A (ja) | 2008-01-25 | 2011-03-31 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | 化合物 |
| WO2011062885A1 (en) | 2009-11-23 | 2011-05-26 | Schering Corporation | Fused bicyclic pyrimidine derivatives and methods of use thereof |
| UY33241A (es) * | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
| ES2562959T3 (es) | 2010-02-26 | 2016-03-09 | Evotec International Gmbh | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| JP6306035B2 (ja) * | 2012-11-09 | 2018-04-04 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 医薬組成物のためのスルホキシミン置換キナゾリン |
| AU2014301295C1 (en) * | 2013-06-28 | 2018-03-15 | Evotec International Gmbh | Sulfoximine substituted quinazolines and their use as MNK1 and/or MNK2 kinase inhibitors |
-
2014
- 2014-11-28 US US15/101,620 patent/US10093660B2/en active Active
- 2014-11-28 CA CA2929742A patent/CA2929742C/en active Active
- 2014-11-28 EP EP14808895.8A patent/EP3077383B1/en active Active
- 2014-11-28 ES ES14808895.8T patent/ES2693520T3/es active Active
- 2014-11-28 JP JP2016536528A patent/JP6457523B2/ja not_active Expired - Fee Related
- 2014-11-28 AU AU2014359456A patent/AU2014359456B2/en not_active Ceased
- 2014-11-28 WO PCT/EP2014/075890 patent/WO2015082324A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ES2693520T3 (es) | 2018-12-12 |
| US20170174668A1 (en) | 2017-06-22 |
| US10093660B2 (en) | 2018-10-09 |
| CA2929742C (en) | 2022-09-20 |
| WO2015082324A1 (en) | 2015-06-11 |
| EP3077383B1 (en) | 2018-08-22 |
| AU2014359456A1 (en) | 2016-06-09 |
| EP3077383A1 (en) | 2016-10-12 |
| CA2929742A1 (en) | 2015-06-11 |
| AU2014359456B2 (en) | 2019-01-24 |
| JP2016539148A (ja) | 2016-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI902715B (zh) | 作為ｐａｒｐ７抑制劑的嗒酮 | |
| JP6549109B2 (ja) | スルホキシイミン置換キナゾリンならびにｍｎｋ１および／またはｍｎｋ２キナーゼ阻害薬としてのその使用 | |
| JP6306035B2 (ja) | 医薬組成物のためのスルホキシミン置換キナゾリン | |
| JP5639197B2 (ja) | 医薬組成物のためのヘテロシクロアルキル含有チエノピリミジン | |
| EP2513108B1 (fr) | NOUVEAUX DERIVES D' (HETEROCYCLE-PIPERIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE OU D' (HETEROCYCLE-PYRROLIDINE CONDENSEE)-(PIPERAZINYL)-1-ALCANONE ET LEUR UTILISATION COMME INHIBITEURS DE p75 | |
| CN108699080A (zh) | 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物 | |
| JP2016539148A (ja) | 医薬組成物のためのスルホキシイミン置換キナゾリン | |
| JP6479854B2 (ja) | 医薬組成物のためのスルホキシイミン置換キナゾリン | |
| CN101103031B (zh) | 用于治疗增生性疾病的吡咯并嘧啶衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171017 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171017 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180703 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180705 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180928 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181204 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181220 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6457523 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |